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ABSTRACT
Hemoglobin glycation index (HGI), calculated as the difference between the 
observed value of HbA1 and the predicted HbA1c based on plasma glucose concentration, 
is a measure of the individual tendency toward non-enzymatic hemoglobin glycation 
which has been found to be positively associated with nephropathy in subjects with 
diabetes. In this cross-sectional study we aimed to evaluate whether higher HGI levels 
are associated with impaired kidney function also among nondiabetic individuals.
The study group comprised 1505 White nondiabetic individuals stratified in 
quartiles according to HGI levels. Estimated glomerular filtration rate (eGFR) was 
calculated by using the MDRD equation. 
Individuals in the intermediate and high HGI groups exhibited a worse metabolic 
phenotype with increased levels of visceral obesity, total cholesterol, triglycerides, 
inflammatory biomarkers such as hsCRP and white blood cells count and lower 
values of HDL and insulin sensitivity assessed by Matsuda index in comparison to the 
lowest quartile of HGI. Subjects in the intermediate and high HGI groups displayed 
a graded decrease of eGFR levels in comparison with the lowest quartile of HGI. In 
a logistic regression analysis individuals in the highest quartile of HGI exhibited 
a significantly 3.6-fold increased risk of having chronic kidney disease (95% CI: 
1.13–11.24, P = 0.03) and a significantly 1.6-fold increased risk of having a mildly 
reduced kidney function (95% CI: 1.19–2.28, P = 0.003) in comparison to individuals 
in the lowest HGI group.
In conclusion HGI may be a useful tool to identify nondiabetic individuals with 
an increased risk of having kidney dysfunction. 
INTRODUCTION
Renal dysfunction is becoming a major public health 
problem worldwide. The human and economic burden 
caused by this affection is growing as a consequence of 
its progression to the end stage renal disease, a condition 
requiring dialysis or kidney transplantation, and the 
associated cardiovascular morbidity and mortality [1–3]. 
Given these clinical implications, early identification 
of individuals with impaired renal function is highly 
warranted to counteract the progression of the disease and 
prevent clinical adverse outcomes [3]. 
Impaired glucose metabolism has been found to 
be related with kidney dysfunction [4–5] and several 
studies have demonstrated a correlation between glycated 
hemoglobin (HbA1c) and kidney disease in subjects 
affected by diabetes as well as in non-diabetic population 
[6–8]. HbA1c is a commonly used indicator of glycemic 
control in patients affected by diabetes and a well-
established predictor of diabetic complications [9–11]. 
Additionally, measurement of HbA1c has been suggested 
by the International Expert Committee as a diagnostic 
criterion for diagnosis of diabetes and prediabetes 
conditions [11–13]. 
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It is widely recognized that a strong relationship 
exists between HbA1c and blood glucose levels; however, 
a considerable inter-individual variability of HbA1c 
with regard to blood glucose levels has been observed 
in diabetic subjects as well as in nondiabetic individuals 
[14–22]. Individuals with HbA1c levels persistently 
higher or lower than those expected in consideration of 
their mean blood glucose levels have been identified and 
referred to as having a high or low hemoglobin glycation 
phenotype, respectively [14]. In an attempt to quantify 
the disparity between HbA1c and the other measures 
of blood glucose homeostasis, Hempe et al. developed 
a mathematical method which was termed hemoglobin 
glycation index (HGI) [14]. The HGI is calculated as the 
difference between the observed value of HbA1c and 
the one predicted on the basis of blood glucose levels, 
estimated by inserting plasma glucose concentration into 
a population regression equation expressing the linear 
association between HbA1c and plasma glucose levels 
[14, 17, 18]. HGI is a measure of the degree of hemoglobin 
glycation, and an independent association between HGI 
and microvascular diabetic complications has been 
reported in some studies [14, 17, 18]. In this regard, a 
higher value of HGI has been shown to be associated 
not only with prevalent nephropathy, but also with an 
increased risk to develop kidney disease in subjects with 
diabetes [17, 18]. 
However, whether higher HGI levels may identify 
subjects with a greater risk to have impaired kidney 
function also among nondiabetic individuals has not been 
investigated yet. The aim of this study was therefore to 
evaluate the link between the degree of hemoglobin 
glycation, estimated by HGI, and renal function in a large 
cohort of White subjects without diabetes.
RESULTS
The whole study cohort comprised 1505 individuals, 
of whom 683 (45.5%) were male. The mean age was 
47 ± 15 years and mean body mass index (BMI) was 
29 ± 6 kg/m2. Table 1 shows the anthropometric and 
biochemical features of the study subjects stratified 
according to quartiles of HGI levels. 
We found that age was significantly different between 
the four study groups; subjects in the high (quartile 4) 
and intermediate (quartile 3 and 2) HGI groups were 
older than individuals in the low HGI group (quartile 1). 
After adjusting for age and gender, significant difference 
between the four study groups were found with respect to 
BMI, waist circumference and fat mass, with a progressive 
increase of these adiposity measures in the intermediate and 
high HGI groups in comparison to low HGI subjects. 
By design individuals in the intermediate and 
high HGI groups exhibited progressively higher levels 
of HbA1c in comparison to the lowest quartile of HGI, 
however no differences in fasting, 1 hour and 2 hour post-
challenge glucose levels were detected between the four 
study groups.
After adjusting for age, gender and BMI, we found 
that higher HGI levels were associated with a worse 
cardio-metabolic phenotype. A higher proportion of 
subjects in the high HGI group were current smokers in 
comparison to the low HGI group. A graded increase in the 
levels of total cholesterol, triglycerides, and inflammatory 
biomarkers such as high sensitivity C reactive protein 
(hsCRP) and white blood cell (WBC) count was 
observed in the intermediate and high HGI groups in 
comparison with the lowest quartile of HGI. Furthermore, 
in comparison to individuals in the lowest HGI group, 
those in the intermediate and high HGI groups displayed 
a significant decrease in high density lipoprotein (HDL) 
cholesterol levels, and insulin sensitivity assessed by the 
Matsuda index. Subjects in the intermediate and high HGI 
groups were more likely to have metabolic syndrome. A 
higher proportion of subjects in the intermediate and high 
HGI groups was treated with angiotensin-converting-
enzyme inhibitor (ACE) inhibitors and angiotensin 
receptor blockers. A higher proportion of subjects in the 
high HGI quartile was taking diuretics and statins.  No 
significant difference between the study groups were 
detected in terms of systolic and diastolic blood pressure, 
hematocrit and hemoglobin levels. 
Notably, a significant and negative correlation 
between HGI and estimated glomerular filtration rate 
(eGFR) was observed, with subjects in the intermediate 
and high HGI groups exhibiting a graded decrease of 
eGFR levels in comparison with the lowest quartile 
of HGI (Table 2 and Figure 1). Moreover even after 
adjustment for metabolic syndrome diagnosis, anti-
hypertensive treatments and statin therapy in addition to 
gender and BMI, subjects in the high HGI group displayed 
significantly lower levels of eGFR in comparison to the 
low HGI group (P ≤ 0.02). 
Additionally, we found that spot urine albumin/
creatinine ratios (ACR), a known marker of kidney 
damage, was increased in the intermediate HGI group 
and, even more, in the high HGI group in comparison with 
the lowest quartile of HGI (Table 2). The difference in 
ACR levels between the lowest and the highest quartile 
of HGI remained statistically significant after adjusting 
for metabolic syndrome diagnosis, anti-hypertensive 
treatments and statin therapy in addition to gender and 
BMI (P ≤ 0.02).   
Next, we evaluated the prevalence of chronic kidney 
disease (CKD, defined as eGFR˂60 ml/min/1.73 m2) and 
mildly reduced kidney function (defined as eGFR 90–60 
ml/min/1.73 m2) in the study population. As expected, 
since the whole study cohort was composed by nondiabetic 
subjects, the proportion of study participants with CKD 
was low (1.8%); however, we observed that the proportion 
of individuals with CKD was progressively increased in 
the intermediate and high HGI groups as compared to the 
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lowest HGI group (P ≤ 0.05 and P ≤ 0.01 respectively) 
(Table 2 and Figure 2A). Of 1505 individuals examined, 
391 had a mildly reduced kidney function (26%) and a 
significant increase in the proportion of subjects with 
mildly reduced kidney function was found in the highest 
HGI quartile in comparison to the other HGI groups 
(P ≤ 0.01 vs quartile 1 and 2 of HGI, P ≤ 0.05 vs quartile 
3 of HIGI) (Table 2 and Figure 2B).
A logistic regression model adjusted for gender 
was used to estimate the association between HGI levels 
and the risk of impaired kidney function (Table 3). 
As compared to individuals in the lowest quartile of 
Table 1: Anthropometric and metabolic characteristics of the study subjects stratified according 
to hemoglobin glycation index
Variables Whole study subjects
1 Quartile
 (–2.55;–0.16)
2 Quartile
 (–0.16;0.4)
3 Quartile
(0.4;0.25) 
4 Quartile
(0.25;1.09) P
Gender (Male/Female) 683/822 168/209 169/206 166/210 180/197 0.75
Age (yrs) 47 ± 15 43 ± 15 44 ± 14 48 ± 15 £££ ### 51 ± 13 £££ ### $$$ < 0.0001§
BMI (kg/m2) 29 ± 6 28.1 ± 5.7 28.9 ± 5.9 29.2 ± 5.6 £££ 30.9 ± 6.6 £££ ### $$$ < 0.0001*
Waist circumference (cm) 99 ± 14 96 ± 13 98 ± 14 99 ± 15 ££ 104 ± 16 £££ ### $$$ < 0.0001*
Fat Mass (%) 32.1 ± 10 31.1 ± 11 31.5 ± 10 32.1 ± 9 34.2 ± 8 £££ ## $ 0.03*
Current smokers N. (%) 281 (22%) 57 (19%) 74 (22%) 63 (20%) 87 (27%) £ 0.02
SBP (mmHg) 126 ± 17 125 ± 17 125 ± 17 125 ± 18 128 ± 16 0.13
DBP (mmHg) 78 ± 11 77 ± 11 78 ± 10 78 ± 11 79 ± 10 0.96
Fasting glucose (mg/dl) 92 ± 11 92 ± 11 92 ± 11 93 ± 10 92 ± 12 0.16
1-h post-load glucose (mg/dl) 150 ± 43 145 ± 45 146 ± 40 150 ± 43 161 ± 43 0.21
2-h post-load glucose (mg/dl) 120 ± 31 114 ± 30 118 ± 31 121 ± 31 128 ± 32 0.11
Fasting insulin (µU/ml) 13 ± 9 12 ± 7 13 ± 10 13 ± 8 15 ± 11 0.40
1-h insulin (µU/ml) 109 ± 85 96 ± 67 110 ± 96 110 ± 85 119 ± 92 0.77
2-h insulin (µU/ml) 96 ± 90 80 ± 73 96 ± 80 96 ± 84 116 ± 95 £££ 0.08
Matsuda insulin sensitivity index 
(mg x L2 x mmol-1 x mU-1 x min-1) 74 ± 48 84 ± 49 78 ± 52 72 ± 47 ££ 66 ± 45 £££ 0.05
HbA1c (%) 5.4 ± 0.4 5.0 ± 0.3 5.4 ± 0.2 £££ 5.6 ± 0.2 £££ ### 5.8 ± 0.2 £££ ### $$$ < 0.0001
Total cholesterol (mg/dl) 197 ± 38 191 ± 39 197 ± 37 200 ± 37 ££ 201 ± 39 ££ 0.03
HDL (mg/dl) 52 ± 14 53 ± 14 52 ± 14 51 ± 14 £ 50 ± 15 ££ # 0.01
Triglycerides (mg/dl) 119 ± 67 108 ± 64 115 ± 65 121 ± 68 ££ 130 ± 70 £££ # 0.01
hsCRP (mg/l) 3.0 ± 3 2.5 ± 3.0 2.9 ± 3.0 3.0 ± 3.0 £ 3.7 ± 3.0 ££ 0.03
WBC count (x109/l) 6840 ± 1919 6163 ± 1517 6751 ± 1725 £££ 6917 ± 2087 £££ 7151 ± 1852 £££ ### < 0.0001
Hematocrit (%) 42.3 ± 4.8 42.2 ± 4.2 42.6 ± 5.8 42.2 ± 4.3 42.9 ± 5.4 0.71
Hemoglobin (g/l) 13.9 ± 1.5 13.9 ± 1.5 13.9 ± 1.5 13.8 ± 1.5 13.9 ± 1.5 0.12
Metabolic syndrome, No (%) 425 (28%) 84 (22%) 91 (24%) 111 (29%) £ 139 (36%) £££ # $ < 0.0001
ACE inhibitor or  Angiotensin 
receptor blocker therapy, No (%)
440 (29%) 82 (21%) 89 (23%) 111 (29%) £ 158 (41%) £££ ## $$ < 0.0001
Diuretics, No (%) 191 (12%) 27 (7%) 34 (9%) 51 (13%) 79 (20%) £££ ## $ < 0.0001
Calcium channel blockers, No (%) 147 (10%) 35 (9%) 35 (9%) 36 (10%) 41 (11%) 0.97
Statin therapy, No 146 (10%) 26 (7%) 29 (7%) 34 (9%) 57 (15%) £££ ### $$ 0.001
Data are means  ±  SD. Fasting, 1-h, 2-h insulin, triglycerides, HDL, hsCRP, and ERS were log transformed for statistical 
analysis, but values in the table represent back transformation to the original scale. Categorical variables were compared 
by χ2 test. Comparisons between the four groups were performed using a general linear model for multiple comparisons. 
P values refer to results after analyses with adjustment for age, gender, and BMI. § P values refer to results after analyses with 
adjustment for gender. *P values refer to results after analyses with adjustment for gender and age.  
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; hsCRP: high sensitivity C reactive 
protein; HDL: high density lipoprotein; ERS: erythrocytes sedimentation rate; WBC: white blood cell count; ACE: 
angiotensin-converting-enzyme.
£ P < 0.05 vs Quartile 1 of HGI;  ££ P < 0.01 vs Quartile 1 of HGI; £££ P < 0.001 vs Quartile 1 of HGI.
# P < 0.05 vs Quartile 2 of HGI; ## P < 0.01 vs Quartile 2 of HGI; ### P < 0.001 vs Quartile 2 of HGI.
$ P < 0.05 vs Quartile 3 of HGI; $$ P < 0.01 vs Quartile 3 of HGI; $$$ P < 0.001 vs Quartile 3 of HGI
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HGI, those in the highest quartile of HGI exhibited a 
significantly 3.6-fold increased OR of having CKD (95% 
CI: 1.13–11.24, P = 0.03). An increased OR of CKD 
was also observed in individuals in quartile 3 of HGI, 
even though it did not reach the threshold for statistical 
significance (2.06, 95% CI: 0.61–6.91, P = 0.24). Similar 
results were found when BMI, and smoking habit were 
included in the logistic regression model in addition to 
gender (Table 3). Subjects in the highest quartile of HGI 
had an increased risk of CKD in comparison to the lowest 
HGI group (OR: 3.44; 95% CI:1.01–12.54, P = 0.05) 
even after adjusting for metabolic syndrome diagnosis in 
addition to gender and smoking habit.
Accordingly, individuals in the highest quartile of 
HGI had a significantly 1.6-fold increased OR of having 
a mildly reduced kidney function (95% CI: 1.19–2.28, P 
= 0.003) in comparison with the lowest HGI group in a 
logistic regression model adjusted for gender. Even after 
adjustment for BMI or metabolic syndrome diagnosis, and 
smoking habit in addition to gender the OR of subjects in 
the highest HGI quartile to have a mildly reduced kidney 
function remained significantly increased in comparison to 
individuals in the lowest quartile of HGI (Table 3).  
DISCUSSION
Given its strong relationship with plasma glucose 
levels, HbA1c is considered as the gold standard to assess 
glucose control and efficacy of therapy in patients affected 
by diabetes [9]. Moreover, assessment of HbA1c values is 
becoming commonly used also in subjects without history 
of diabetes as a diagnostic test for diabetes and prediabetes 
conditions [11–13]. Although it is widely recognized that 
plasma glucose concentrations are the major determinant 
of HbA1c levels, a discrepancy between HbA1c and 
other measures of glucose homeostasis including fasting 
plasma glucose [18], self-monitored blood glucose [14, 15, 
19, 20], continuous glucose monitoring data [16, 21], and 
fructosamine [23, 24], has been reported and found to be 
consistent over time [22]. Remarkably, several studies have 
demonstrated that there are subjects with inappropriately 
low or high HbA1c levels relatively to their blood glucose 
concentrations not only among individuals affected by 
diabetes but also within nondiabetic population [14–22, 
23, 24]. The existence of a biological inter-individual 
variation of HbA1c independent from circulating glucose 
levels suggests that factors other than glucose may 
influence hemoglobin glycation process, such as cellular 
permeability, 2,3-diphosphoglycerate concentration, levels 
and activity of glycolytic or deglycating enzymes [17, 22]. 
The HGI, which is calculated by subtracting from 
the observed HbA1c value the one expected on the 
basis of blood glucose concentrations, was developed in 
order to quantify the magnitude and the direction of the 
discordance commonly found between HbA1c and other 
measures of glucose control [14]. Higher HGI levels 
have been proposed to identify a phenotype of glucose 
metabolism characterized by an increased susceptibility 
to protein glycation, and tissue accumulation of advanced 
glycation end products (AGEs) [14, 25]. Notably, subjects 
Figure 1: Estimated glomerular filtration rate (eGFR) in study participants stratified according to hemoglobin 
glycation index (HGI). 
Oncotarget79580www.impactjournals.com/oncotarget
Table 2: Renal function of the study subjects stratified according to hemoglobin glycation index
Variables Whole study subjects
1 Quartile
 (–2.55;–0.16)
2 Quartile
 (–0.16;0.4)
3 Quartile
(0.4;0.25) 
4 Quartile
(0.25;1.09) P
Creatinine (mg/dl) 0.78 ± 0.17 0.76 ± 0.17 0.77 ± 0.17 0.78 ± 0.17 0.80 ± 0.22 ££ 0.05
eGFR (ml/min/1.73m2) 107 ± 22 105 ± 23 104 ± 21 102 ± 22 £ 99 ± 24 £££ ### 0.001
ACR (μg/mg) (n = 401) 14 ± 11 11 ± 9 13 ± 11 13 ± 11 18 ± 13 ££ # $ 0.04
CKD (eGFR ˂ 60  ml/min/1.73 m2) 27 (1.8%) 3 (0.8%) 4 (1%) 8 (2.1%) £ 12 (3.2%) ££ # 0.02
Mildly reduced kidney function (eGFR: 90–60  
ml/min/1.73 m2) 391 (26.1%) 88 (23%) 87 (23%) 93 (25%) 123 (33%) ££ ## $ 0.001
Data are means  ±  SD. Categorical variables were compared by χ2 test. Comparisons between the four groups were performed 
using a general linear model for multiple comparisons. P values refer to results after analyses with adjustment for gender and BMI. 
eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease; ACR = spot urine albumin creatinine ratio.
£ P < 0.05 vs Quartile 1 of HGI;  ££ P < 0.01 vs Quartile 1 of HGI; £££ P < 0.001 vs Quartile 1 of HGI.
# P < 0.05 vs Quartile 2 of HGI; ## P < 0.01 vs Quartile 2 of HGI; ### P < 0.001 vs Quartile 2 of HGI.
$ P < 0.05 vs Quartile 3 of HGI.
Figure 2: Prevalence of chronic kidney disease (A) and mildly reduced kidney function (B) in study population stratified in quartiles of 
hemoglobin glycation index (HGI).
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Table 3: Odds ratios (95% CI) by multiple logistic regression models for renal dysfunction in 
relation to HGI groups
Chronic kidney disease
eGFR ˂ 60 ml/min/1.73 m2
Study groups OR  95% CI P 
Model 1
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.74 0.16–3.34 0.69
Quartile 3 of HGI 2.06 0.61–6.91 0.24
Quartile 4 of HGI 3.58 1.14–11.24 0.03
Model 2
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.69 0.15–3.13 0.63
Quartile 3 of HGI 2.00 0.59–6.83 0.27
Quartile 4 of HGI 3.47 1.07–11.21 0.04
Model 3
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.30 0.03–2.91 0.30
Quartile 3 of HGI 0.90 0.17–4.54 0.89
Quartile 4 of HGI 3.44 1.01–12.54 0.05
Mildly reduced kidney function
eGFR 60–90 ml/min/1.73 m2
Study groups OR  95% CI P 
Model 1
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.98 0.69–1.37 0.89
Quartile 3 of HGI 1.09 0.78–1.52 0.63
Quartile 4 of HGI 1.65 1.19–2.28 0.003
Model 2
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.95 0.66–1.38 0.81
Quartile 3 of HGI 1.07 0.74–1.56 0.71
Quartile 4 of HGI 1.52 1.05–2.18 0.03
Model 3
Quartile 1 of HGI 
(reference category) 1 — ---
Quartile 2 of HGI 0.93 0.63–1.38 0.73
Quartile 3 of HGI 0.99 0.67–1.47 0.96
Quartile 4 of HGI 1.46 1.01–2.14 0.05
Model 1: adjusted for gender; Model 2: Model 1 + BMI, and smoking habit; Model 3: Model 1+ metabolic syndrome, and 
smoking habit.
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affected by type 1 diabetes with higher HGI levels, 
calculated using self-glucose monitoring data, exhibited 
a higher prevalence and incidence of nephropathy and 
retinopathy [17]. Moreover, an analysis of patients with 
type 2 diabetes participating to the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial has 
shown a positive association between HGI, calculated 
using fasting glucose levels to predict HbA1c value, and 
the risk of both micro-vascular complications, and total 
mortality in the intensive treatment subgroup [18]. In 
addition, it has been recently reported that individuals with 
high HGI showed a significant increase in carotid intima 
media thickness, a well validated proxy of subclinical 
atherosclerosis [26]. Altogether these evidences highlight 
the crucial role of intracellular accumulation of glycated 
proteins, as estimated by high HGI, in the pathogenesis of 
organ damage caused by hyperglycemia.
Nevertheless, whether higher HGI levels may identify 
subjects with an increased risk of having an impaired 
kidney function among nondiabetic individuals is currently 
unsettled. Keeping in mind that an enhanced non-enzymatic 
glycation of intracellular proteins may alter their structure 
and function, and can promote AGEs accumulation resulting 
in tubular and glomerular injury [27, 28], we tested the 
hypothesis that a higher rate of non-enzymatic glycation of 
intracellular proteins, measured by HGI, is associated with 
kidney dysfunction also in nondiabetic subjects. In this 
cross-sectional study, we observed that nondiabetic subjects 
with higher HGI levels display a lower eGFR in comparison 
with individuals with lower HGI. Moreover, we found a 
positive association between HGI and albuminuria, a well-
established marker of kidney damage and independent risk 
factor for cardiovascular morbidity and mortality [29,30]. 
Remarkably, we found that subjects with higher HGI levels 
displayed an increased risk of having CKD or a mildly 
reduced renal function in comparison to individuals with 
low HGI, even after adjustment for several confounders. 
In this regard, it should be noted that the risk of kidney 
dysfunction was found to be significantly increased only 
in subjects in the highest quartile of HGI, whereas it did 
not reach statistical significance in the third quartile of 
HGI. This observation supports the hypothesis that the 
link between HGI and impaired kidney function becomes 
significantly evident when the burden of intracellular 
glycated proteins exceeds the efficiency of compensatory 
factors, including glyoxalase system and NADPH-
dependent enzymes, such as aldehyde reductase and aldose 
reductase, known to play an essential role in counteracting 
protein glycation and AGEs formation [31–33].
Importantly, levels of fasting, 1 hour and 2 hour 
post-load glucose were not significantly different between 
the study groups supporting the idea that the association 
between HGI and kidney dysfunction is not dependent of 
other measures of glucose metabolism in the extracellular 
compartment. Moreover,  even though HbA1c levels 
may be affected by erythrocytes turnover, no significant 
difference in hemoglobin and hematocrit was observed 
between the study groups. 
The underlying mechanism(s) by which high HGI 
may contribute to kidney dysfunction are still indefinite. 
Several cardio-metabolic risk factors, such as obesity, 
dyslipidemia, insulin resistance, chronic inflammation 
have been shown to represent important risk factors for 
the development of kidney disease [34–36]. Accordingly, 
we observed that high HGI is associated with a worse 
cardio-metabolic risk profile as demonstrated by increased 
values of BMI, waist circumference, total cholesterol and 
triglycerides, inflammatory biomarkers such as hsCRP 
and WBC count, and lower levels of HDL and insulin 
sensitivity in individuals with higher HGI levels as 
compared with those having low HGI. 
Considering that HGI has been found to reflect the 
levels of AGEs in the tissues [25], a plausible candidate 
linking HGI with renal dysfunction may be represented 
by a raised burden of AGEs in the kidney of subjects 
with higher HGI levels. Non-enzymatic glycation of 
polypeptides, including hemoglobin, occurs via Maillard 
reaction, which is also involved in the formation of 
AGEs [25]. A large body of evidence has demonstrated 
that AGEs, directly or by binding specific receptors that 
recognize AGE-modified proteins (RAGE), may induce 
pro-inflammatory, oxidative and pro-fibrotic responses 
which are implicated in the development of kidney injury 
[27, 28, 37–39].
The present cross-sectional findings supporting 
the link between the individual tendency toward a raised 
intracellular protein glycation, estimated by higher values 
of HGI, and kidney dysfunction may have important 
clinical implications. Since kidney function impairment and 
higher concentrations of albumin in urine are independent 
predictors of cardiovascular morbidity and mortality in 
the general population [1–3, 30], an early identification 
of subjects with kidney damage is a crucial step to most 
effectively target intervention in an attempt to counteract 
the development of adverse clinical outcomes. It is well 
recognized that higher HbA1c levels are associated with 
kidney dysfunction not only in diabetic population but also 
in subjects without diabetes [6–8]. Our results suggest that 
HGI may be useful to identify among non-diabetic subjects 
with similar levels of HbA1c those with a “high glycation” 
phenotype having an increased risk of kidney disease.  
The present study has several strengths and potential 
limitations that merit comment. The major strengths of the 
study include the large sample size, an extended clinical 
characterization with anthropometric and metabolic data 
collected by trained staff, the centralization of biochemical 
analyses including a rigorously standardized HbA1c 
measurement, the exclusion of conditions known to affect 
red cell survival, such as hemoglobinopathies and major 
blood loss, the use of oral glucose tolerance test (OGTT) 
data rather than fasting glucose alone as reported in 
previous studies [18]. 
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Nevertheless, in interpreting our data some 
limitations should be taken in account. First all 
biochemical parameters, including plasma glucose during 
OGTT and HbA1c, were measured once. Even though 
this approach is commonly used in clinical research, 
between-individual variability of glucose homeostasis 
parameters may have led to some imprecision in the 
stratification of study population into HGI quartiles. 
Second, eGFR was used to identify and classify kidney 
disease. Isotopes clearance measurements may provide 
a more accurate evaluation of renal function; however, 
estimation of renal function by using MDRD equation is 
widely employed in large epidemiologic studies as well 
as in clinical practice, making our observations applicable 
to public health practice settings. Another limitation 
of the present study is the lack of a detailed diagnosis 
of kidney disease since no kidney biopsy or evaluation 
of specific kidney disease biomarkers  was performed. 
Furthermore, insulin sensitivity was evaluated by the 
Matsuda index rather than by the gold standard technique 
euglycemic hyperinsulinemic clamp. However, it should 
be considered that euglycemic hyperinsulinemic clamp is 
a time-consuming and expensive procedure not feasible 
in large clinical studies, and Matsuda index has been 
shown to be highly correlated with whole-body insulin 
sensitivity assessed by euglycemic hyperinsulinemic 
clamp [40]. Additionally, we have recently demonstrated 
an association between HGI values with insulin 
sensitivity, assessed by the gold standard euglycemic 
hyperinsulinemic clamp [26]. Moreover,  given the cross-
sectional design of the study our observations suggest 
only an association between the rate of non-enzymatic 
glycation of intracellular proteins assessed by HGI and 
prevalent kidney dysfunction, and no causal relationship 
between the two phenomena may be established. 
Moreover all participants to the present study were White, 
and whether our results may be extendible to other ethnic 
groups, including Blacks, Hispanics, American Indians, 
that have been shown to exhibit higher levels of HbA1c 
than White subjects [41], warrants further investigations.
In conclusion HGI may represent a helpful tool 
to identify a subset of subjects harboring a greater risk 
of having kidney dysfunction not only among patients 
affected by diabetes mellitus, as reported by prior studies, 
but also within nondiabetic population.   
MATERIALS AND METHODS
We analyzed 1505 nondiabetic subjects participating 
to the CATAnzaro MEtabolic RIsk factors (CATAMERI) 
study, a cross-sectional study assessing cardio-metabolic 
risk factors in individuals carrying at least one risk 
factor including dysglycemia, overweight/obesity, 
hypertension, dyslipidemia, and family history for diabetes 
[26, 42, 43]. Exclusion criteria comprised: diagnosis of 
diabetes, history of any malignant disease, heart failure, 
gastrointestinal diseases associated with bleeding or 
malabsorption, autoimmune diseases, acute or chronic 
infections, acute or chronic pancreatitis, accumulation 
diseases such as amyloidosis and hemochromatosis, 
history of drug abuse, self-reporting alcohol consumption 
of > 20 g⁄day, positivity for antibodies to hepatitis C 
virus (HCV) or hepatitis B surface antigen (HBsAg), 
treatments able to modulate glucose metabolism, 
including corticosteroids and hypoglycemic agents. 
Anthropometrical parameters including BMI, waist 
circumference, blood pressure, body composition assessed 
by bioelectrical impedance, and biochemical data of study 
participants were collected after an over-night fasting. 
Each subject underwent  a 75 g OGTT with 0, 30, 60, 90 
and 120 min sampling for measurement of plasma glucose 
and insulin levels.
The protocol was approved by the Hospital ethical 
committee (Comitato Etico Azienda Ospedaliera “Mater 
Domini”) and all study participants gave written informed 
consent in accordance with principles of the Declaration 
of Helsinki.
Analytical determinations
HbA1c levels were assessed with high performance 
liquid chromatography using a National Glycohemoglobin 
Standardization Program (NGSP) certified automated 
analyzer (Adams HA-8160 HbA1C analyzer, Menarini, 
Italy). Serum and urine creatinine concentrations 
were measured by an automated technique based on a 
Creatinine Jaffè compensated method for serum and urine 
(Roche Diagnostics) implemented in an auto-analyzer. 
Albuminuria was measured in fresh urine samples by 
immuneturbidimetry (Roche Diagnostics).  An automated 
particle counter (Siemens Healthcare Diagnostics ADVIA® 
120/2120 Haematology System,Milan,Italy) was employed 
to measure hemoglobin, hematocrit, and WBC count. 
Glucose, triglycerides, total and HDL cholesterol 
levels were assessed by enzymatic methods (Roche, Basel, 
Switzerland). Plasma insulin levels were measured with 
a chemiluminescence-based assay (Immulite®,Siemens 
Healthcare GmbH,Erlangen, Germany). Levels of hsCRP 
were assessed by an automated instrument (CardioPhase® 
hsCRP,Milan,Italy).
Calculation
Fasting plasma glucose and HbA1c data of the study 
population were used to estimate the linear relationship 
between the two parameters as described in previously 
published studies [18, 26]. The predicted level of HbA1c 
for each subject was calculated by inserting fasting 
plasma glucose concentration into the linear regression 
equation (HbA1c = 0.0158 * fasting glucose levels (mg/dl) 
+4.0311) [26]. HGI values were computed by subtracting 
the predicted levels of HbA1c from those observed, as 
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previously described [18, 26]. Study participants were 
stratified into quartiles according to their HGI values. 
The Matsuda index of insulin sensitivity was 
computed as follows: 10,000/square root of [fasting 
glucose (mmol/L) × fasting insulin (mU/L)] × [mean 
glucose × mean insulin during OGTT] [40].
eGFR was calculated by using the MDRD equation: 
eGFR = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) where 
Scr is serum creatinine [44]. CKD was defined as eGFR 
< 60 ml/min/1.73 m2 and mildly reduced renal function was 
identified when eGFR was 90–60 ml/min/1.73 m2 [45].
Spot urine albumin (μg)/creatinine (mg) ratios 
(ACR) were calculated for 401 subjects, of whom albumin 
and creatinine levels in the morning urine samples were 
available [46]. 
Metabolic syndrome was defined as having three or 
more of the following criteria [47]: waist circumference > 
102 cm in men and > 88 cm in women, triglycerides > 150 
mg/dl or on treatment for elevated triglycerides, HDL < 40 
mg/dl in men and < 50 mg/dl in women or on treatment 
for reduced HDL, blood pressure > 130/85 mmHg or on 
antihypertensive treatment, fasting glucose ≥ 100 mg/dl.
Statistical analysis
Given their skewed distribution, triglycerides, HDL, 
hsCRP, fasting, 1-hour, and 2-hour post-load insulin were 
natural log transformed for statistical analyses. Continuous 
data are expressed as mean ± SD. χ2 test was employed to 
compare categorical variables. We used a general linear 
model to test pairwise differences in anthropometric and 
metabolic parameters among the study groups. A multivariate 
logistic regression analysis was performed to determine the 
association between the study groups and kidney function 
impairment. We considered statistically significant a two-
sided P value ≤ 0.05. All analyses were carried out using 
SPSS software program Version 17.0 for Windows.
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